Kalyan Roy: How Platelet-Rich Plasma Accelerates Tissue Repair and Regeneration
Kalyan Roy, Transfusion Medicine Specialist at Square Hospitals LTD, shared a post on LinkedIn:
”Platelet-Rich Plasma (PRP): Harnessing the Body’s Own Healing Power
Regenerative medicine is transforming healthcare, and Platelet-Rich Plasma (PRP) has emerged as one of its most promising biologic therapies.
Unlike conventional treatments that primarily relieve symptoms, PRP promotes tissue repair by utilizing the patient’s own platelets, concentrated to 3–8 times their normal level.
These platelets release a rich cocktail of growth factors and cytokines that stimulate healing, angiogenesis, collagen synthesis, stem cell recruitment, and modulation of inflammation.
Key Growth Factors in PRP
- PDGF – Cell proliferation and tissue repair
- TGF-β – Collagen synthesis and cartilage healing
- VEGF – Angiogenesis and vascular regeneration
- EGF – Skin and epithelial repair
- IGF-1 – Muscle and bone regeneration
- FGF – Fibroblast activation and tendon healing
Clinical Applications
- Knee Osteoarthritis
- Chronic Tendinopathies (Tennis Elbow, Achilles Tendinopathy)
- Sports Injuries
- Androgenetic Alopecia (Hair Restoration)
- Chronic Non-healing Wounds
- Oral and Maxillofacial Surgery
- Plastic Surgery and Skin Rejuvenation
How Does PRP Work?
Hemostasis, followed by Controlled Inflammation, followed by Cellular Proliferation, and finally Tissue Remodeling
Current Evidence
The strongest scientific evidence supports PRP in mild-to-moderate knee osteoarthritis, chronic tendinopathies, and androgenetic alopecia. While outcomes are encouraging, standardized preparation protocols and high-quality clinical trials remain essential to optimize its therapeutic potential.
PRP is not simply a platelet concentrate—it represents a shift toward biologic, personalized, and regenerative medicine, where the patient’s own blood becomes a powerful tool for healing.
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 23:18Claire Hills: New Paper on Immune Surveillance and Immune Evasion of Senescent Cells
-
Aug 14, 2026, 23:16Are We Overlooking What Matters Most to Women with Von Willebrand Disease? – RPTH Journal
-
Aug 14, 2026, 23:15Markus Müller: A New Base Editing Approach Targeting PCSK9 to Lower Cholesterol Levels
-
Aug 14, 2026, 23:14Chokri Ben Lamine: Avatrombopag in Hematology – Dosing and Monitoring
-
Aug 14, 2026, 23:13Bianca Rocca: PRECISE-DAPT Score Identifies Bleeding Risk After CABG in Patients With POAF
-
Aug 14, 2026, 19:04Ravi Kumar: Why Lupus Anticoagulant Predicts Clots, Not Bleeding
-
Aug 14, 2026, 18:53Veli Bakalov: The Number Every Hematologist Should Know in Polycythemia Vera
-
Aug 14, 2026, 18:41Marta Velia Antonini: Can Nitric Oxide Protect the ECMO Circuit Without Systemic Anticoagulation?
-
Aug 14, 2026, 18:30Irina Gontschar: What the Epkinly FDA Review Teaches Us About Sponsor Oversight